Relic Technologies reported a consolidated net loss of ₹102.75 lakh for the quarter ended June 30, 2026 (Q1FY27), marking a substantial improvement from the ₹368.32 lakh loss recorded in the same period of FY25. The Board of Directors approved the unaudited financial results on August 13, 2026, noting that the company has commenced revenue-generating operations through its trading activities in pharmaceuticals, nutraceuticals, wellness products, healthcare products, chemicals, and allied products.

Financial Performance

The consolidated revenue from operations stood at ₹35.49 lakh for the quarter, a sharp decline from ₹128.15 lakh in Q1FY26. This contraction in topline activity contributed to total expenses of ₹162.07 lakh, which included employee benefit expenses of ₹78.79 lakh and other expenses of ₹42.99 lakh. Consequently, the group reported a profit before tax of (₹104.21 lakh). After accounting for a net tax benefit of ₹1.46 lakh, the net loss attributable to owners of the parent was ₹64.88 lakh.

In contrast, the standalone entity delivered a net profit of ₹21.47 lakh for the quarter, compared to a net profit of ₹9.84 lakh in Q1FY25. Standalone revenue from operations was ₹21.15 lakh, while other income contributed ₹43.00 lakh. Total standalone expenses were contained at ₹41.98 lakh, with employee benefits at ₹11.19 lakh and other expenses at ₹8.49 lakh.

What the Numbers Show

The divergence between standalone profitability and consolidated losses highlights the ongoing financial drag from subsidiaries. While Relic Technologies Limited itself generated a surplus, its subsidiaries—Relic Pharma Limited and Truhealthy Wellness Private Limited—reported a combined net loss of ₹124.22 lakh against revenues of ₹14.34 lakh for the quarter. This indicates that the group’s overall financial health remains heavily dependent on the turnaround or cost optimization within these subsidiary entities, despite the parent company’s initial success in launching new trading verticals.

Auditor Review

The unaudited standalone and consolidated financial results were reviewed by D. Kothary & Co., the statutory auditors, who issued an unmodified opinion. The review was conducted in accordance with Standard on Review Engagements (SRE) 2410 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Relic Technologies Limited has scheduled its 35th Annual General Meeting (AGM) for August 13, 2026, to seek shareholder approval for the appointment of Sachin Srivastava as Whole-time Director and Chief Executive Officer (CEO) for a period of three years effective from June 13, 2026. The company has reported a standalone net profit of ₹54.20 lakhs for the financial year ended March 31, 2026, compared to a net loss of ₹171.87 lakhs in the previous year.

The Board recommends the appointment of Mr. Srivastava, subject to the approval of members. The proposed remuneration includes a salary of up to ₹25,00,000 per annum and variable pay of up to ₹10,00,000 per annum. The remuneration is subject to a yearly review, with the first increment due after April 1, 2027, capped at a maximum of 10% per annum.

Shareholders will also consider a special resolution to approve material related party transactions with Truhealthy Wellness Private Limited, a subsidiary of the company. The proposed transactions include purchases and sales of goods and services for an aggregate value not exceeding ₹10 Crores and loans to the subsidiary not exceeding ₹25 Crores. During the financial year 2025-26, the company had provided loans amounting to ₹558 lakhs to the subsidiary.

Furthermore, the AGM will seek approval for the Employee Stock Option Plan 2025 (ESOP 2025). The plan envisages granting up to 1,10,000 options, exercisable into 1,10,000 equity shares of ₹10 each, to eligible employees of the company and its subsidiaries. The Board has also proposed extending the benefits of this plan to employees of subsidiary companies.

The AGM will be held through video conferencing and other audio-visual means. Remote e-voting will be available from August 10, 2026, to August 12, 2026. The record date for determining shareholder eligibility is August 6, 2026.